Parallel synthesis of cell-penetrating peptide conjugates of PMO toward exon skipping enhancement in Duchenne muscular dystrophy.

We describe two new methods of parallel chemical synthesis of libraries of peptide conjugates of phosphorodiamidate morpholino oligonucleotide (PMO) cargoes on a scale suitable for cell screening prior to in vivo analysis for therapeutic development. The methods represent an extension of the SELection of PEPtide CONjugates (SELPEPCON) approach previously developed for parallel peptide-peptide nucleic acid (PNA) synthesis. However, these new methods allow for the utilization of commercial PMO as cargo with both C- and N-termini unfunctionalized. The synthetic methods involve conjugation in solution phase, followed by rapid purification via biotin-streptavidin immobilization and subsequent reductive release into solution, avoiding the need for painstaking high-performance liquid chromatography purifications. The synthesis methods were applied for screening of PMO conjugates of a 16-member library of variants of a 10-residue ApoE peptide, which was suggested for blood-brain barrier crossing. In this work the conjugate library was tested in an exon skipping assay using skeletal mouse mdx cells, a model of Duchene's muscular dystrophy where higher activity peptide-PMO conjugates were identified compared with the starting peptide-PMO. The results demonstrate the power of the parallel synthesis methods for increasing the speed of optimization of peptide sequences in conjugates of PMO for therapeutic screening.

[1]  Michael J Gait,et al.  A chemical view of oligonucleotides for exon skipping and related drug applications. , 2014, Nucleic acid therapeutics.

[2]  J. Mendell,et al.  Eteplirsen for the treatment of Duchenne muscular dystrophy , 2013, Annals of neurology.

[3]  P. Deuss,et al.  Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo , 2013, Organic & biomolecular chemistry.

[4]  M. Gait,et al.  Development of a general methodology for labelling peptide–morpholino oligonucleotide conjugates using alkyne–azide click chemistry† †Electronic supplementary information (ESI) available: Experimental section and supplementary figures. See DOI: 10.1039/c3cc46067c Click here for additional data file. , 2013, Chemical communications.

[5]  M. Wood,et al.  Splicing therapy for neuromuscular disease☆ , 2013, Molecular and Cellular Neuroscience.

[6]  M. Wood,et al.  Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. , 2013, Human gene therapy.

[7]  S. Hammond,et al.  Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment , 2012, Molecular therapy. Nucleic acids.

[8]  H. Moulton,et al.  Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. , 2012, The American journal of pathology.

[9]  M. Masserini,et al.  Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[10]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[11]  F. Muntoni,et al.  Targeting RNA to treat neuromuscular disease , 2011, Nature Reviews Drug Discovery.

[12]  P. Camelliti,et al.  Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[14]  H. Moulton,et al.  Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. , 2010, Biochimica et biophysica acta.

[15]  Chantal Pichon,et al.  Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers , 2009, British journal of pharmacology.

[16]  B. Lebleu,et al.  Improved cell-penetrating peptide–PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle , 2008, Nucleic acids research.

[17]  P. Iversen,et al.  Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer , 2008, Proceedings of the National Academy of Sciences.

[18]  P. Iversen,et al.  Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure–activity studies , 2008, Nucleic acids research.

[19]  H. Moulton,et al.  Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function , 2008, Human molecular genetics.

[20]  P. Iversen,et al.  Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  B. Lebleu,et al.  Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide , 2007, Nucleic acids research.

[22]  K. Barry Sharpless,et al.  Polytriazoles as Copper(I)‐Stabilizing Ligands in Catalysis. , 2004 .

[23]  P. Iversen,et al.  Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. , 2004, Bioconjugate chemistry.

[24]  Federica Gemignani,et al.  Systemically delivered antisense oligomers upregulate gene expression in mouse tissues , 2002, Nature Biotechnology.

[25]  R. Kole,et al.  Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. , 1998, Biochemistry.

[26]  B. Lebleu,et al.  RNA targeting in cells by peptide conjugates of peptide nucleic acids (PNA) , 2008 .

[27]  D. Cistola,et al.  Structural features of synthetic peptides of apolipoprotein E that bind the LDL receptor. , 1995, Journal of lipid research.